NAPG mutation in family members with hereditary hemorrhagic telangiectasia in China

Yu Xu1†, Yong-Biao Zhang2†, Li-Jun Liang1, Jia-Li Tian1, Jin-Ming Lin3, Pan-Pan Wang3, Rong-Hui Li3, Ming-Liang Gu3,4* and Zhan-Cheng Gao1*

Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is a disease characterized by arteriovenous malformations in the skin and mucous membranes. We enrolled a large pedigree comprising 32 living members, and screened for mutations responsible for HHT.

Methods: We performed whole-exome sequencing to identify novel mutations in the pedigree after excluding three previously reported HHT-related genes using Sanger sequencing. We then performed in silico functional analysis of candidate mutations that were obtained using a variant filtering strategy to identify mutations responsible for HHT.

Results: After screening the HHT-related genes, activin A receptor-like type 1 (ACVRL1), endoglin (ENG), and SMAD family member 4 (SMAD4), we did not detect any co-segregated mutations in this pedigree. Whole-exome sequencing analysis of 7 members and Sanger sequencing analysis of 16 additional members identified a mutation (c.784A > G) in the NSF attachment protein gamma (NAPG) gene that co-segregated with the disease. Functional prediction showed that the mutation was deleterious and might change the conformational stability of the NAPG protein.

Conclusions: NAPG c.784A > G may potentially lead to HHT. These results expand the current understanding of the genetic contributions to HHT pathogenesis.

Keywords: Hereditary hemorrhagic telangiectasia, Whole-exome sequencing, NAPG

Background
Hereditary hemorrhagic telangiectasia (HHT) is a group of related disorders inherited in an autosomal dominant fashion, characterized by the development of arteriovenous malformations (AVMs) in the skin and mucous membranes. AVMs may occur anywhere in the body but are most apparent on the lips, tongue, face, fingertips, and the nasal, buccal, and gastrointestinal mucosa [1]. AVMs may also be found in internal organs such as the brain, lung, and liver. Due to the thin walls and proximity to the skin or mucosal surfaces, vessels are prone to rupture and bleeding with minimal injury. Epistaxis and mucocutaneous telangiectasias are the most common clinical manifestations [2, 3].

HHT is thought to affect people regardless of ethnicity and has been reported in many nations [2, 4, 5], with an estimated prevalence ranging from 1 in 5000 to 8000 [4]. Three genes, namely activin A receptor-like type 1...
Sequencing reactions were conducted using Applied Bio-
well Filter Plate 30 K (Pall, Port Washington, NY, USA).
and PCR products were purified using an AcroPrep 384-
All PCR was performed using the touchdown method,
using Primer-Premier 5.0 (PREMIER Biosoft Interna-
family members to detect mutations in these genes. In
SMAD4
and sequenced the DNA of the proband and his
(M) was young. The occurrence of epistaxis and epilepsy was
choscopy results revealed hemorrhagic telangiectasia in
The proband was admitted for hemoptysis, and his bron-
Study subjects and laboratory analysis
The proband was admitted for hemoptysis, and his bron-
bronchoscoppy results revealed hemorrhagic telangiectasia in
the tracheal and bronchial mucosa. The patient disclosed
that he had epilepsy and was prone to epistaxis when he
was young. The occurrence of epistaxis and epilepsy was
also observed in other family members. We collected
blood samples from 23 family members and determined
the platelet count (UnicelDxH 800, Coulter Cellular
Analysis System, FL, USA) and platelet activity (Chrono-
Log, Corporation, MODEL 700, PA, USA). We also col-
lected the medical histories of these family members to
identify the HHT clinical subtype.
Screening previously reported HHT-related genes
We designed primers for all exons of
ACVRL1, ENG, and SMAD4
and sequenced the DNA of the proband and his
family members to detect mutations in these genes. In
brief, primer sets for PCR and sequencing were designed
using Primer-Premier 5.0 (PREMIER Biosoft Interna-
tional, Palo Alto, CA, USA) (Additional file 1: Table 1).
All PCR was performed using the touchdown method,
and PCR products were purified using an AcroPrep 384-
well Filter Plate 30 K (Pall, Port Washington, NY, USA).
Sequencing reactions were conducted using Applied Bio-
systems BigDye Terminator chemistry, and the products
were resolved on an ABI Prism 3730xl DNA Analyzer
(Applied Biosystems). Sequence trace files were analyzed
using Phred/Phrap/Polyphred/Consed software (Univer-
sity of Washington, Seattle, WA, USA). The base-quality
value threshold was set to 20 in Phred (i.e., a 99% prob-
ability that the base is accurate).

WES and variant calling
Within the analyzed HHT pedigree, four affected indi-
viduals, one obligate carrier, and two normal individu-
als (one of them the spouse of a family member) were
selected for WES. The Sure Select Human All Exon
70 Mb kit (Agilent Technologies, Santa Clara, CA,
USA) was used to capture the whole exome. Paired-end
sequencing with a 150-bp read length was conducted
for each sample on a HiSeq X Ten sequencer (Illumina,
San Diego, CA, USA). All reads were mapped to the
human reference genome (hg19) using BWA (version
0.7.5a-r405). PCR duplication was removed using Pic-
ard (version 1.92). GATK (version 3.7) was used to call
the variants. We used Pindel and cn.MOPS software
to detect structural variants and copy number varia-
tions, respectively [9, 10]. Variants were then annotated
using Seattle Seq Annotation 138, sequentially filtered,
and assessed according to the following methodology
described by Sun et al. [11]: (1) removal of ariants with a
global minor allele frequency (MAF) greater than 0.01 in
the dbSNP 138 or 1000 Genomes Project databases; (2)
retention of variants consistent with a model of dominant
disease transmission; (3) removal of variants with MAF
greater than 0.01 in the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project (ESP),
Exome Aggregation Consortium (ExAC), and Interna-
tional Haplotype Map (HapMap) databases; (4) reten-
tion of only possible loss-of-function variants, including
missense, frame-shift, near splice-site, and stop-gain/
stop-loss variants; (5) retention of the variants that
passed manual confirmation using the IGV package; and
(6) retention of variants that are predicted as deleterious
(PolyPhen score > 0.6) or near splice-site variants.

Genotyping of all collected sample using Sanger
sequencing
We designed primers for candidate genes obtained from
the abovementioned process (Additional file 1: Table 2)
and sequenced DNA collected from 16 other pedigree
members. The processes of primer design, PCR amplifi-
cation, DNA sequencing, and variant calling are the same
as those described in the subsection "Screening previ-
ously reported HHT-related genes".

Structure prediction of NSF attachment protein gamma
(NAPG) protein
To evaluate the structure of NAPG and the effect of the
NAPG p.M262V mutation on protein conformation, we
used the following software packages: PSIPRED for secondary structure prediction, Swiss-model for tertiary structure prediction, and Swiss-Pdb Viewer 4.1 for tertiary structure display and manipulation. In Swiss-Pdb Viewer, the following parameters were used: minimum energy, residues within 6 Å to p.M262V, secondary structure as ribbon format, colorful secondary structure by types, and computing H-bonds and van der Waals forces.

Results

Clinical characteristics

The proband of the HHT family was born in 1967 and is from Shanxi province of China. The patient was admitted for hemoptysis, and a chest radiograph did not find any abnormality in his lungs. His laboratory tests, such as platelet counts and coagulation function, were normal. To determine the bleeding site causing hemoptysis, we performed bronchoscopy on this patient. Results showed hemorrhagic telangiectasia in the tracheal and bronchial mucosa (Fig. 1). The patient told us that he had seizures, and there was a higher incidence rate of epistaxis and seizure in his family members than in other residents, especially when the family members were infants or teenagers. Some family members were admitted to the hospital for seizure and were diagnosed with epilepsy. Therefore, we obtained clinical data from the whole family (32 living members), and the pedigree is shown in Fig. 2 (the proband is III-11). Blood samples from 23 family members were collected, 9 of which exhibited epistaxis and 7 were diagnosed with epilepsy when they were infants. Their platelet-related laboratory tests of platelets were normal, with mean platelet counts of 266.30 × 10⁹ ± 65.57 × 10⁹/L (normal range: 150–350 × 10⁹/L) and platelet activity of 71.80 ± 11.85% (normal range: 50–150%).

WES and HHT candidate gene determination

To explore the genetic mechanism underlying this HHT pedigree, we performed WES analysis of four diagnosed patients (II-4, III-5, III-11, and III-13; Fig. 2), one obligate carrier (III-9; Fig. 2), and two unaffected individuals (II-5, and III-1; Fig. 2). The exome sequencing showed a mean coverage of 43- to 109-fold (Additional file 1: Table 3). In total, 282,930 variants, including 282,447 single nucleotide variants and small indels, 25 structural variants, and 458 copy number variants were identified. As 201,332 of these variants had a global MAF larger than 0.01 in the dbSNP138 database, those variants were removed from the variants library. Of the remaining 81,598 variants, 545 were retained for adhering to the autosomal dominant inheritance mode suggested by the pedigree, i.e., mutations carried by the four diagnosed patients and one obligate carrier but not by the two unaffected individuals were retained. By further cross-checking with the NHLBI ESP, ExAC, and HapMap databases, we eliminated 82 variants that had MAFs larger than 0.01. Subsequently, we focused on variants that were missense, frame-shift, splicing, or stop-gain/stop-loss variants and obtained 25 possible loss-of-function variants. After predicting the harmful effects of these 25 variants, we selected 7 deleterious variants and 2 splicing variants as HHT candidates (Fig. 3). These nine variants were located in ARAP3, NAPG, C7orf50, CYP2W1, SRC, DKK2, FNDC1, GOLGA6L2, and EIF3B (Table 1).

We firstly performed Sanger sequencing of DNA of an additional eight members of the pedigree (II-3, III-3, III-6, III-7, III-8, III-10, III-12, and III-14; Fig. 2) at the SNP sites of the nine candidate genes, and found that only NAPG c.784A>G co-segregate with the disease (Fig. 2). To further verify this result, the DNA of eight fourth-generation family members was subjected to Sanger sequencing (IV-4, IV-5, IV-7, IV-8, IV-9, IV-10, IV-11, IV-13 and IV-14; Fig. 2).

Fig. 1 Imaging and bronchoscope results of the proband (III-11). a Normal the proband’s chest X-ray. b The left main bronchus, with telangiectasia evident under the bronchial mucosa (arrow). c Another patient’s bronchoscopy, showing a normal capillary vessel under the bronchial mucosa.
and IV-12; Fig. 2). We found that NAPG c.784A > G was well segregated within this generation (present in all four patients), suggesting its strong correlation with the disease. In addition, after searching the GeneMatcher database [12], we found that NAPG has not been previously reported.

**In silico modeling of the NAPG c.784A > G mutation**

NAPG c.784A > G is located on chromosome 18, resulting in an amino acid change from methionine to valine. MET262 is highly conserved in NAPG across species, even between humans and fruit flies (Fig. 4). Although there is no reported structure for the human NAPG protein, the zebrafish NAPG (75% homologous to the human protein) has been revealed as an elongated all-helix protein composed of 15 α-helices, with four helix hair-pins on the N-terminal and one helix bundle on the Carboxyl-terminal [13]. Based on the homology, the protein structure prediction software produced a similar all-helix protein structure for human NAPG. MET262 resided immediately before α15 close to the C-terminal, which happens to be a ligand (sulfate ion) pocket, as indicated in the zebrafish NAPG structure (Fig. 5a). Given the potential of the MET262VAL mutation to alter the interaction between protein and ligand, we performed in silico modeling of this mutation. MET262 forms a hydrogen bond with PHE259, which is lost after the mutation (Fig. 5b, c), and this could explain why the VAL residue was predicted to have a higher energy than the MET one in the protein (Additional file 1: Table 4). Moreover, the MET262VAL variant changed the spatial conformation of the proximate ASP263, resulting in the formation of two new hydrogen bonds between ASP263 and ASP265 as well as between ASN264 and ALA267 (Fig. 5c). These changes could sabotage the active site of the protein. Therefore, MET262VAL might have changed the conformation and stability of the C-terminal, which is responsible for N-ethylmaleimide-sensitive fusion protein binding [14], leading to NAPG dysfunction.

**Discussion**

HHT is a rare disease known as an autosomal-dominantly inherited vascular malformation syndrome, characterized by telangiectasias and AVMs. Two genes in the transforming growth factor-beta (TGF-β) signaling pathway, ENG and ACVRL1, were discovered almost two decades ago, and mutations in these genes have been reported to cause up to 85% of HHT cases. Besides, 2% of patients with HHT carry SMAD4 mutations [2].

So far, there are no data on the epidemiology of HHT in China. In our study, while genetic screening of the family revealed no mutations in the ENG, ACVRL1, or SMAD4 genes, we identified an A/G mutation in NAPG. NAPG encodes a gamma-soluble NSF attachment protein that mediates platelet exocytosis and controls membrane fusion events [15]. The mutation identified in NAPG caused an amino acid change from methionine to valine, which is predicted to change the stability of
the C-terminal of the protein. As Koseoglu et al. showed that granule exocytosis is required for platelet spreading [16]. We speculate that changes in stability of NAPG may cause a deficiency in platelet spreading.

We assessed platelet counts and activity in the family members that carried NAPG mutation, and observed that only one individual (IV-12, an 8-year-old boy) showed an increased platelet number. All tested family members presented normal platelet activity. These results indicate that NAPG mutation did not influence platelet function in vitro. It is well known that the early formation of blood cell plugs that seal a disrupted endothelial barrier is a repair mechanism that, if altered by an ENG mutation, could play a critical role in vascular pathologies, such as HHT [17]. Similarly, the conformational change in NAPG due to the identified mutation may cause a deficiency in platelet spreading by affecting its exocytosis, which in turn might influence vascular structures and result in HHT.

AVMs in HHT are characterized by a lack of intervening capillaries between arteries and veins. They may occur anywhere in the body and, due to their thin walls and proximity to the skin and mucosal surfaces, are prone to rupture and bleeding with minimal injury. Epistaxis
| CHR Position | Ref/Alt | SNP | GenBank transcript ID | Function | Amino Acid changes | cDNA changes | PolyPhen | CADD Score | Gene | MAF in GnomAD |
|--------------|---------|-----|-----------------------|----------|-------------------|-------------|----------|------------|------|----------------|
| 5            | 141,036,099 | C/T | rs7953884 | NM_022481 | missense | ARG,HIS,VAL | c.3761G > A | 1.632 | 16.68 | ARAP3 | 0.00733 |
| 18           | 1,049,698 | A/G | rs568083670 | NM_00134395 | missense | LYS,GLU,VAL | c.211A > G | 0.957 | 5.54  | NA | 0.000008 |
| 7            | 1,026,318 | C/T | rs369538884 | NM_017781 | missense | ARG,HIS,VAL | c.704G > A | 0.997 | 12.47 | CYP2W1 | 0.000008 |
| 7            | 1,026,318 | C/T | rs369538884 | NM_017781 | missense | ARG,HIS,VAL | c.704G > A | 0.997 | 12.47 | CYP2W1 | 0.000008 |
| 20           | 36,022,675 | C/T | rs146865960 | NM_005417 | missense | THR,MET | c.548C > T | 0.997 | 13.53 | SRC | 0.000008 |
| 4            | 107,845,819 | G/A | rs146683175 | NM_014421 | missense | HIS,LYS,VAL | c.412C > T | 0.999 | 28.70 | DKK2 | 0.001529 |
| 6            | 159,618,528 | C/T | rs374967242 | NM_032532 | missense | TRP,ARG | c.175T > C | 1 | 16.42 | FNDC1 | 0.000325 |
| 15           | 23,685,007 | T/C | rs139919701 | NM_001304388 | frameshift-near-splice | none | c.2602_2614delGGG | - | - | GOLGA6L2 | NA |
| 7            | 2,405,952 | G/A | rs147656962 | NM_001037283 | synonymous-near-splice | ARG,ARG | c.1158G > A | - | 0.95 | EIF3B | 0.002907 |

* Physical position according human reference genome hg19
Ref/Alt: Reference allele/Alternative allele, CHR: chromosome, SNP: single nucleotide polymorphism, MAF: minor allele frequency
Fig. 4 Alignment and conservation of residues among NAPG orthologs. Black highlighting indicates 100% amino acid homology across species; red and cyan highlighting indicates 75% and 50% homology, respectively. The arrow indicates the highly conserved MET262.

Fig. 5 Tertiary structure prediction of NAPG and hydrogen bond changes after MET262>VAL mutation. A, A cartoon representation of the human NAPG structure in the rainbow coloring scheme from the N-terminal (blue) to the Carboxyl-terminal (red); the blue arrow indicates MET262>VAL. B, Hydrogen bonds in wild-type NAPG. C, Hydrogen bonds in NAPG p.262 M > V. Green dotted lines indicate hydrogen bonds. Numbers indicate hydrogen bond distances. The orange arrow indicates a hydrogen bond loss between PHE259 and VAL262. The blue arrows indicate new hydrogen bond formations between ASP263 and ASP265, and between ASN264 and ALA267.
Conclusions

This study used WES to identify a NAPG mutation in a Chinese family cluster of HHT. This gene mutation caused an amino acid change from methionine to valine, sabotaging the protein function by altering its structure, and probably promoting HHT. The discovery expands the current understanding of the genetic contribution to HHT pathogenesis.

Abbreviations

HHT: Hereditary hemorrhagic telangiectasia; WES: Whole-exome sequencing; AVM: Arteriovenous malformations; MAF: Minor allele frequency; ESP: Exome Sequencing Project; ExAC: Exome Aggregation Consortium; HapMap: International Haplotype Map; ACVR1L: Activin A receptor-like type 1; ENG: Endoglin; SMAD: SMAD family member 4; NAPG: NSF attachment protein gamma; NHLBI: National Heart, Lung, and Blood Institute.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12890-021-01524-4.

References

1. Dittus C, Streiff M, Ansell J. Bleeding and clotting in hereditary hemorrhagic telangiectasia. World J Clin Cases. 2015;3(4):330–7. https://doi.org/10.1177/019459919889955.
2. Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat. 2002;19(2):140–8. https://doi.org/10.1002/humu.10026.
3. Plachcu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32(3):291–7. https://doi.org/10.1002/ajmg.1320320302.
4. Westermann CJ, Rosina AF, De Vries V, de Coteau PA. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in Afro-Caribbean population of The Netherlands Antilles: a family screening. Am J Med Genet A. 2003;116A(4):324–8. https://doi.org/10.1002/ajmg.a.10002.
5. Gang N, Khunger M, Gupta A, Kumar N. Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med. 2014;5:191–206. https://doi.org/10.2147/JBM.S545295.
6. Jia J, Zhang J, Zhao LD, et al. Clinical features and screening of ACVR1L1 gene in II hereditary hemorrhagic telangiectasia. Zhonghua Yi Xue Za Zhi. 2012;92(16):1107–11. https://doi.org/10.3760/cma.j.issn.1003-9406.2013.04012.
7. Yu Q, Cheng Z, Yi YF, Peng HL. Gene analysis of a Chinese family with hereditary hemorrhagic telangiectasia and its curative effect of
thalidomide. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(4):1136–41. https://doi.org/10.7534/j.issn.1009-2137.2017.04.031.
8. Chen YJ, Yang QH, Liu D, et al. Clinical and genetic characteristics of Chinese patients with hereditary haemorrhagic telangiectasia-associated pulmonary hypertension. Eur J Clin Investig. 2015;45(10):1016–24. https://doi.org/10.1111/eci.12138.
9. Ye K, Schulz MH, Long Q, et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009;25(21):2865–71. https://doi.org/10.1093/bioinformatics/btp694.
10. Klambauer G, Schwarzauer K, Mayr A, et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res. 2012;40(9):e69. https://doi.org/https://10.1093/nar/gks003.
11. Sun LY, Zhang YB, Jiang L, et al. Identification of the gene defect responsible for severe hypercholesterolaemia using whole-exome sequencing. Sci Rep. 2015;5:11380. https://doi.org/10.1038/srep11380.
12. Sobreira N, Chiariello F, Vallee D, et al. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015:36(10):928–30. https://doi.org/10.1002/humu.22844.
13. Bitto E, Bingman CA, Kondrashov DA, et al. Structure and dynamics of gamma-SNAP: insight into flexibility of proteins from the SNAP family. Proteins. 2008;70(1):93–104. https://doi.org/10.1002/prot.21468.
14. Tani K, Shibata M, Kawase K, et al. Mapping of functional domains of gamma-SNAP. J Biol Chem. 2003;278(15):13531–8. https://doi.org/10.1074/jbc.M213205200.
15. Lemons PP, Chen D, Bernstein AM, Bennett MK, Whiteheart SW. Regulated secretion in platelets: identification of elements of the platelet exocytosis machinery. Blood. 1997;90(4):1490–500.
16. Koseoglu S, Peters CG, Fitch-Tewfik JL, et al. VAMP-7 links granule exocytosis to actin reorganization during platelet activation. Blood. 2015;126(5):651–60. https://doi.org/10.1182/blood-2014-12-61844.
17. Rossi E, Lopez-Novoa JM, Bernabeu C. Endoglin involvement in integrin-mediated cell adhesion as a putative pathogenic mechanism in hereditary hemorrhagic telangiectasia type 1 (HHT1). Front Genet. 2015;5:457. https://doi.org/10.3389/fgene.2014.00457.
18. Pollak JS, Saluja S, Thabet A, Henderson KJ, Denbou N, White RI Jr. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2006;17(1):35–44; quiz 45. https://doi.org/https://10.1097/01.RVI.0000191410.13974.B6.
19. Yang W, Liu A, Hung AL, et al. Lower risk of intracranial arteriovenous malformation hemorrhage in patients with hereditary hemorrhagic telangiectasia. Neurosurgery. 2016;78(5):684–93. https://doi.org/10.1227/NEU.0000000000001103.
20. Lesca G, Olivieri C, Burchichon N, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med. 2007;9(1):14–22. https://doi.org/10.1097/gim.0b013e31802d8373.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.